New RNA cocktail takes on advanced liver cancer in early trial
NCT ID NCT05097911
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a new RNA-based drug (MTL-CEBPA) together with two approved immunotherapy drugs (atezolizumab and bevacizumab) in people with advanced liver cancer who have not had prior systemic treatment. The main goals are to find the safest dose and to see how the body handles the combination. Only 33 participants will be enrolled at a single center in Singapore.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTL-CEBPA (RNA drug) combined with atezolizumab and bevacizumab
What this could lead to
If this combination proves safe and effective, it could offer a new first-line treatment option for advanced liver cancer.
What could go wrong
This is a very early phase 1 trial with only 33 participants, so safety and dosing are the main focus. The drug combination may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore